$BSX · Boston Scientific Corporation
Boston Scientific Corporation filed an amended Schedule 13G with the SEC regarding its holdings in RenovoRx, Inc. The filing states that in August 2026, Boston Scientific sold 543,971 shares of RenovoRx common stock. As a result, as of September 30, 2026, Boston Scientific reports that it no longer beneficially owns more than 5% of RenovoRx’s outstanding common stock.
The amendment updates the original Schedule 13G that Boston Scientific filed on February 10, 2022. According to the filing, Boston Scientific now reports zero shares beneficially owned, with no sole or shared voting power and no sole or shared dispositive power over RenovoRx shares. The reported ownership percentage is 0%.
Boston Scientific describes this amendment as its final amendment to the Schedule 13G and an exit filing, meaning it is no longer required to report its RenovoRx position under the applicable beneficial ownership rules. The filing does not state the price or terms of the August 2026 share sale.